Hormone Receptor Status Influences the Impact of Body Mass Index and Hyperglycemia on the Risk of Tumor Relapse in Early-stage HER2-positive Breast Cancer Patients

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2021 May 5

PMID 33948122

Citations 5

Authors

Francesca Ligorio

Luca Zambelli

Achille Bottiglieri

Lorenzo Castagnoli

Emma Zattarin

Riccardo Lobefaro

Arianna Ottini

Andrea Vingiani

Serenella M Pupa

Giulia V Bianchi

Giuseppe Capri

Giancarlo Pruneri

Filippo De Braud

Claudio Vernieri

Affiliations

Soon will be listed here.

Abstract

Background: High body mass index (BMI) has been associated with worse clinical outcomes in patients with early-stage breast cancer (BC), and its negative effects could be mediated by hyperglycemia/diabetes. However, the prognostic impact of high BMI in early-stage HER2-positive (HER2+) BC patients remains controversial.

Methods: We conducted a retrospective study to investigate the impact of baseline BMI or glycemia on relapse-free survival (RFS) and overall survival (OS) in patients with surgically resected, stage I-III HER2+ BC treated with standard-of-care, trastuzumab-containing adjuvant biochemotherapy. The optimal BMI and glycemia cut-off values for RFS were identified through maximally selected rank statistics. Cox regression models were used to assess the impact of BMI, glycemia and other relevant variables on clinical outcomes.

Results: Among 505 patients included in the study, a BMI cut-off of 27.77 kg/m was identified as the best threshold to discriminate between patients with low BMI ( = 390; 77.2%) or high BMI ( = 115; 22.8%). At multivariable analysis, higher BMI was associated with significantly worse RFS [hazard ratio 2.26; 95% confidence interval (CI): 1.08-4.74, = 0.031] and worse OS (hazard ratio 2.25, 95% CI 1.03-4.94, = 0.043) in the whole patient population. The negative impact of high BMI was only observed in patients with hormone receptor (HR)-negative/HER2+ BC (hazard ratio 2.29; 95% CI: 1.01-5.20; = 0.047), but not in patients with HR-positive (HR+)/HER2+ BC (hazard ratio 1.36; 95% CI: 0.61-3.07, = 0.452). By contrast, hyperglycemia (⩾109 mg/dl) at baseline was associated with a trend toward significantly worse RFS at multivariable analysis only in patients with HR+/HER2+ BC (hazard ratio 2.52; 95% CI: 0.89-7.1; = 0.080).

Conclusions: High BMI is associated with worse clinical outcomes in early-stage HR-/HER2+ BC patients treated with trastuzumab-containing adjuvant biochemotherapy, while baseline hyperglycemia could be a predictor of worse RFS in HR+/HER2+ BC patients. Prospective studies are needed to investigate if modifying patient BMI/glycemia during treatment can improve clinical outcomes.

Citing Articles

Effect of body mass index on breast cancer prognosis: a focus on ER/PR status and subtype-specific recurrence risk.

Shen Q, Zhao L, Lu M Am J Transl Res. 2024; 16(11):6467-6476.

PMID: 39678546 PMC: 11645606. DOI: 10.62347/WJIQ1560.

Fluctuations in serum lipid levels during neoadjuvant treatment as novel predictive and prognostic biomarkers for locally advanced breast cancer: a retrospective analysis based on a prospective cohort.

Chen X, Zhao Y, Wang Y, Ye Y, Xu S, Zhou L Lipids Health Dis. 2024; 23(1):261.

PMID: 39175000 PMC: 11340160. DOI: 10.1186/s12944-024-02140-x.

Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.

Chan D, Vieira R, Abar L, Aune D, Balducci K, Cariolou M Int J Cancer. 2022; 152(4):572-599.

PMID: 36279884 PMC: 10092239. DOI: 10.1002/ijc.34322.

Can Bariatric and Metabolic Surgery Prevent Cancer Recurrence in Obesity-Related Neoplasms?.

Chiappetta S, Bottino V, Farina A Obes Surg. 2022; 32(10):3469-3470.

PMID: 35902541 DOI: 10.1007/s11695-022-06230-6.

Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications.

Ligorio F, Zambelli L, Fuca G, Lobefaro R, Santamaria M, Zattarin E Ther Adv Med Oncol. 2022; 14:17588359221079123.

PMID: 35281350 PMC: 8908398. DOI: 10.1177/17588359221079123.

References

Arpino G, Wiechmann L, Osborne C, Schiff R . Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008; 29(2):217-33. PMC: 2528847. DOI: 10.1210/er.2006-0045. View

Kim J, Guan K . mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol. 2019; 21(1):63-71. DOI: 10.1038/s41556-018-0205-1. View

Vernieri C, Casola S, Foiani M, Pietrantonio F, De Braud F, Longo V . Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. Cancer Discov. 2016; 6(12):1315-1333. PMC: 5140697. DOI: 10.1158/2159-8290.CD-16-0615. View

Ravacci G, Brentani M, Tortelli T, Torrinhas R, Santos J, Logullo A . Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells. Biomed Res Int. 2015; 2015:838652. PMC: 4659962. DOI: 10.1155/2015/838652. View

Corominas-Faja B, Vellon L, Cuyas E, Buxo M, Martin-Castillo B, Serra D . Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer. Histol Histopathol. 2016; 32(7):687-698. PMC: 5784426. DOI: 10.14670/HH-11-830. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim Jr H, Fumagalli D . Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. J Clin Oncol. 2017; 35(13):1421-1429. PMC: 5455460. DOI: 10.1200/JCO.2016.69.7722. View

Miranda P, DeFronzo R, Califf R, Guyton J . Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J. 2005; 149(1):33-45. DOI: 10.1016/j.ahj.2004.07.013. View

Krop I, Kim S, Gonzalez Martin A, LoRusso P, Ferrero J, Badovinac-Crnjevic T . Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017; 18(6):743-754. DOI: 10.1016/S1470-2045(17)30313-3. View

10.

Gianni L, Pienkowski T, Im Y, Tseng L, Liu M, Lluch A . 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17(6):791-800. DOI: 10.1016/S1470-2045(16)00163-7. View

11.

Hudis C . Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007; 357(1):39-51. DOI: 10.1056/NEJMra043186. View

12.

Wulffele M, Kooy A, de Zeeuw D, Stehouwer C, Gansevoort R . The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004; 256(1):1-14. DOI: 10.1111/j.1365-2796.2004.01328.x. View

13.

Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Stephan-Otto Attolini C . Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2016; 541(7635):41-45. DOI: 10.1038/nature20791. View

14.

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio I . Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(8):1194-1220. DOI: 10.1093/annonc/mdz173. View

15.

Vitug A, Newman L . Complications in breast surgery. Surg Clin North Am. 2007; 87(2):431-51, x. DOI: 10.1016/j.suc.2007.01.005. View

16.

Sestak I, Distler W, Forbes J, Dowsett M, Howell A, Cuzick J . Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010; 28(21):3411-5. DOI: 10.1200/JCO.2009.27.2021. View

17.

Mazzarella L, Disalvatore D, Bagnardi V, Rotmensz N, Galbiati D, Caputo S . Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. Eur J Cancer. 2013; 49(17):3588-97. DOI: 10.1016/j.ejca.2013.07.016. View

18.

Protani M, Coory M, Martin J . Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 123(3):627-35. DOI: 10.1007/s10549-010-0990-0. View

19.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

20.

Irwin M, McTiernan A, Baumgartner R, Baumgartner K, Bernstein L, Gilliland F . Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol. 2005; 23(4):774-82. PMC: 3000612. DOI: 10.1200/JCO.2005.04.036. View